论文部分内容阅读
1商品名Yervoy2开发与上市厂商本品由百时美施贵宝制药公司开发,于2011年4月在美国首次上市,同年8月在欧盟上市。3适应证本品用于治疗不能手术切除或转移性的黑色素瘤患者。4药理本品通过与细胞毒性T淋巴细胞抗原(CTLA-4)结合阻断CTLA-4与其配体CD80/CD86的相互作用。
1 Product Name Yervoy2 Developed and Listed Manufacturer This product was developed by Bristol-Myers Squibb in the United States in April 2011 and listed in the EU in August of the same year. 3 Indications This product is used to treat patients with unresectable or metastatic melanoma. 4 Pharmacology This product blocks the interaction of CTLA-4 with its ligand CD80 / CD86 by binding to the cytotoxic T lymphocyte antigen (CTLA-4).